New Zealand's PHARMAC Picks Up Douglas To Dump Novartis; Funds Dr. Reddy's Risperidone, Schering-Plough's Avanza
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Beginning Nov. 1, Schering-Plough's antidepressant Avanza (mirtazapine) will be listed on New Zealand's Pharmaceutical Schedule for second-line treatment of severe depression, the Pharmaceutical Management Agency reported
You may also be interested in...
Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs
PERTH, Australia - Using sole-supply providers, New Zealand generic drug prices were considerably cheaper than corresponding drugs in Australia, Britain and Canada, according to the Pharmaceutical Management Agency's annual review for 2009
Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs
PERTH, Australia - Using sole-supply providers, New Zealand generic drug prices were considerably cheaper than corresponding drugs in Australia, Britain and Canada, according to the Pharmaceutical Management Agency's annual review for 2009
Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs
In New Zealand the government is the primary funder of pharmaceuticals, with 21 District Health Boards holding the budget for both the community Pharmaceutical Schedule and hospital purchases.